Back to top
more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$2.72 USD

2.72
2,534,770

+0.17 (6.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)

by Zacks Equity Research

Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.

    Is a Beat in Store for Amarin (AMRN) This Earnings Season?

    by Zacks Equity Research

    Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

    What's in Store for Innoviva (INVA) This Earnings Season?

    by Zacks Equity Research

    Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.

    Allogene's Shares March Higher, Can It Continue?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.

    Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (ALLO) Outperforming Other Medical Stocks This Year?

    Here's Why Momentum Investors Will Love Allogene Therapeutics (ALLO)

    by Zacks Equity Research

    Does Allogene Therapeutics (ALLO) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results

    by Zacks Equity Research

    Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

    Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?

    by Zacks Equity Research

    Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Why You Shouldn't Bet Against Allogene Therapeutics (ALLO) Stock

    by Zacks Equity Research

    Allogene Therapeutics (ALLO) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

    Will Allogene Continue to Surge Higher?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.